WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Yankees' slugger Aaron Judge strikes out four times, hears boos on promotional bobblehead day
15 people suffer minor injuries in tram accident at Universal Studios theme park in Los Angeles
Zelensky, Stoltenberg agree to hold urgent meeting of Ukraine
Miriam: Death Of A Reality Star review
Stalin's lost city: Inside the crumbling remains of once
Crawford works 6 solid innings and the Red Sox deal the struggling Pirates a 5th straight loss
Masters champ Scottie Scheffler posts a 63 and leads the RBC Heritage by 1 shot
Former Spain coach Del Bosque to head the commission overseeing beleaguered soccer federation
Crawford works 6 solid innings and the Red Sox deal the struggling Pirates a 5th straight loss
WADA defends pick of Swiss prosecutor under scrutiny in review of Chinese swimmers case
Zelensky, Stoltenberg agree to hold urgent meeting of Ukraine